Bile acids (BAs) regulate multiple aspects of metabolism (1). The oldest known roles for BAs are in cholesterol homeostasis: BAs promote absorption of dietary cholesterol, solubilize biliary cholesterol for excretion, and are themselves the major product of liver cholesterol catabolism. More recently, BAs have been recognized as signaling molecules, repressing their own synthesis as well as that of triglyceride (TG) in the liver and promoting incretin secretion in the gut. Many of these actions occur through activation of BA receptors such as the nuclear receptor FXR and the G protein–coupled receptor TGR5 (1). In addition, BAs can act as mediators of the unfolded protein response (2).

Given the variety of metabolic pathways modulated by BAs, pharmacological manipulation of these molecules has become of interest for obesity and diabetes. Pharmacological use of exogenous BAs is limited by their narrow therapeutic window due to the toxicity of selected secondary BAs and the effect of chenodeoxycholic acid (CDCA) to increase LDL cholesterol (LDL-C) (3). Nonetheless, ursodeoxycholic acid (UDCA) has been gainfully used for dissolution of cholesterol gallstones or treatment of primary biliary cirrhosis (4,5). BA sequestrants are effectively used to reduce LDL-C and improve glycemic control in type 2 diabetes (T2D) (6). FXR and TGR5 agonists have also been developed, although their use has been limited by efficacy (for TGR5 agonists) or side effects (increased LDL-C and pruritus, for FXR agonists) (3,7). There has also been a surge of interest in the effects of bariatric surgery on endogenous BAs, and whether BA signaling can account for some of its insulin-sensitizing effects (8,9).

The primary products of the BA synthetic pathway in humans are CDCA and cholic acid (CA). They in turn are modified by gut microbiota to yield lithocholic acid (LCA) and deoxycholic acid (DCA), two secondary BAs, respectively, as well as other secondary and tertiary BAs (Fig. 1). Conversion of CDCA to CA in the liver requires 12α-hydroxylation, encoded by Cyp8b1. Individual BAs differ in their physicochemical properties, such that individual BAs or subsets of BAs can affect downstream metabolic pathways differentially (1,10). For example, whereas CDCA is a potent agonist of FXR, with a K_m in the micromolar range, DCA and LCA have been suggested as partial antagonists of FXR (11).

We have recently shown that in rodents, insulin inhibits the production of 12α-hydroxy BAs by suppressing transcription of Cyp8b1 (12). Conversely, the insulin resistance (IR) characteristic of T2D would be expected to increase levels of 12α-hydroxylated BAs, as has indeed been observed in multiple mouse models of diabetes (13–17). However, in determining the consequences of this shift in BA composition in human diabetes, one should be mindful of important differences in BA metabolism between mammalian species. Unlike in humans, in rodents, CDCA can be 6-hydroxylated, leading to the formation of hydrophilic muricholic acids that are unable to promote dietary cholesterol absorption (18) or agonize FXR (19,20). It is therefore unclear how mechanisms of BA action identified in mice would apply to human diabetes and IR.

The goal of this work was to critically test the hypothesis that there exists a correlation between insulin sensitivity and BA 12α-hydroxylation in humans. To this end, we measured 13 BA species in plasma collected after an overnight fast from 200 healthy individuals with normal glucose tolerance and a range of insulin sensitivities, as assessed by hyperinsulinemic-euglycemic clamps, and from 35 patients with T2D. Secondly, we sought to characterize the relationship between BA subtypes, BA levels, and metabolic parameters.
FIG. 1. Reminder of BA pathway. The enzyme 12α-hydroxylase (CYP8B1) is responsible for the conversion of CDCA into CA, GCA, glycocholic acid; GC, glycoccholic acid; HDCA, hyodeoxycholic acid; UDCA, ursodeoxycholic acid; TLCA, tauroliotholic acid; TCDCA, taurochenodeoxycholic acid.

RESEARCH DESIGN AND METHODS

Study population. The study population included 200 nondiabetic subjects (103 women and 97 men) and 35 patients with T2D (18 women and 17 men). The nondiabetic subjects were part of the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study (www.egir.org), which recruited apparently healthy Caucasians in 19 centers in 14 European countries between June 2002 and July 2004 (21). Study participants were between 30 and 60 years of age, and blood pressure (<140/<90 mmHg), plasma cholesterol (<7.8 mmol/L), TGs (<4.6 mmol/L), and fasting and 2-h plasma glucose (7.0 and 11.1 mmol/L) were within established limits. Exclusion criteria were the presence of overt cardiovascular disease, chronic systemic diseases (hypertension, diabetes, dyslipidemia, inflammatory, and neoplastic diseases), class III obesity, and carotid stenosis (>=50%) or calcified carotid plaques and drug treatment for hypertension, diabetes, dyslipidemia, or obesity or steroid use. The 200 individuals in the current study were selected to cover the entire 8–10-fold range of insulin sensitivity of the original cohort (21). The T2D group was recruited at our Clinical Research Center; their mean diabetes duration was 9 years, their mean HbA1c was 7.9 ± 1.0%, and they were on stable treatment with metformin ≥ sulfonulary (nine patients were also receiving insulin). The protocol was approved by the institutional ethics committee of the University of Pisa.

Study procedures. All study subjects received a euglycemic insulin clamp (using an insulin infusion rate of 240 μmol · min⁻¹ · m⁻² of body surface area), performed as previously described (22). Insulin sensitivity was calculated as the insulin-mediated whole-body glucose disposal during the final 40 min of the 2-h clamp normalized to the fat-free mass (M) divided by the steady-state plasma insulin concentration during the same time interval (M/I, in units of μmol · min⁻¹ · kg⁻¹ · m⁻²) (23). In the RISC subjects, insulin secretion was derived from mathematical modeling of the plasma glucose and C-peptide response to an oral glucose tolerance test with the use of C-peptide deconvolution (24). A fatty liver index (FLI) was calculated as previously described (25). Plasma lipid profile was determined by standard methods, plasma hormone concentrations (insulin, proinsulin, glucagon, and adiponectin) were measured by radioimmunoassay, and circulating metabolites were determined by a metabolomics platform (26).

BA measurements. Aliquots (0.1 mL) of plasma collected after an overnight fast were spiked with internal standard (10 μL cholate-d4, 25 μmol/L), mixed with 1 mL ice-cold acetonitrile, vortexed, and centrifuged for 10 min at 11,000g. Supernatant was dried under nitrogen at 45°C and resuspended in 100 μL 55/45 (volume for volume) MeOH/H2O, containing 5 mmol/L ammonium formate. Ten microliters was injected into LCMS (Waters Quattro Micro with Waters 2705 Alliance HPLC). Quantitative standard curves were used, and deuterated internal standards were used to measure recovery. Subgrouping and hydrophobicity of the measured BAs are listed in Table 1. Hydrophobicity index (HI) was calculated using the published method (27).

Statistical analysis. Data are given as mean ± SD or median and (interquartile range) for normally or nonnormally distributed variables, respectively. Group differences were analyzed by Kruskal-Wallis or Mann-Whitney test, as appropriate. Principal component analysis was carried out on correlations using a Varimax method for orthogonal factor rotation. Multivariate and partial regression analyses were performed by standard methods. A P value ≤0.05 was considered statistically significant. All statistical analyses were performed using JMP7.0.

### TABLE 1

| Name (abbreviation) | Primary | 12α-OH Conjugated | HI |
|---------------------|---------|--------------------|----|
| CDCA               | X       | 0.59               |    |
| Glycocholic acid (GCA) | X | X | 0.51 |
| Taurocholic acid (TCA) | X | X | 0.46 |
| UDCA               | X       | −0.31              |    |
| Hyodeoxycholic acid (HDCA) | X | −0.23 |
| LCA                | X       | 1.13               |    |
| Taurolithocholic acid (TLCA) | X | X | 1.00 |
| CA                 | X       | X                  | 0.13 |
| Glycocolic acid (GCA) | X | X | 0.07 |
| Taurocotic acid (TCA) | X | X | -    |
| DCA                | X       | 0.72               |    |
| Glycodeoxycholic acid (GDCA) | X | X | 0.65 |
| Taurodeoxycholic acid (TDCA) | X | X | 0.59 |

RESULTS

Healthy subjects. The anthropometric and metabolic characteristics of our cohort of nondiabetic subjects are summarized in Table 2. Upon subdividing the group into quartiles of clamp-derived insulin sensitivity (M/I), insulin-resistant subjects had a similar age as insulin-sensitive individuals but were heavier and more hyperinsulinemic. Among BAs, CDCA and its conjugated forms were the most abundant species, accounting for 43 ± 15% of the total BA pool, followed by DCA and its conjugates (29 ± 11% of the pool). Circulating BAs comprised roughly equal parts of primary versus secondary, conjugated versus unconjugated, and 12α-hydroxylated versus non–12α-hydroxylated BAs. The HI averaged 0.47. Across quartiles of M/I, more insulin-resistant individuals tended to have slightly higher total plasma BAs (Table 2).

Based on our findings in experimental animals, we predicted that IR would increase the ratio of 12α-hydroxylated to non–12α-hydroxylated BAs; we therefore analyzed these subcategories. We found that the sum of 12α-hydroxylated species (CA, DCA, and their conjugates) increased significantly with IR, whereas non–12α-hydroxylated species, as a category, were unaltered. The increase of 12α-hydroxylated BAs was not accounted for by any individual species, as five out of six 12α-hydroxylated species showed the same upward trend. Conversely, there were no significant associations of insulin sensitivity with the balance of unconjugated versus conjugated BAs or of secondary versus primary BAs, although the increase of DCA caused trends in these two categories (Table 2). An important factor in determining BA bioactivity is their relative hydrophobicity, which predicts their ability to traverse membranes, bind FXR, and promote lipid and cholesterol absorption in the intestine. Thus, we also examined the hydrophobicity of the BA pool by calculating the estimated HI of the BA pool of each subject (27). We found no significant alteration in hydrophobicity across quartiles of insulin sensitivity (Table 2).

If variations of BA pool composition were a component of the IR syndrome, one would expect to see associations with other metabolic parameters linked to this condition.
We used principal components analysis to dissection out relationships between BAs and other metabolic parameters in healthy subjects (Supplementary Table 1). The ratio of 12α-hydroxy/non–12α-hydroxy BAs had its highest loading on a factor characterized, in addition to a lower M/I, by higher BMI, waist-to-hip ratio, and mean blood pressure; increased fasting and postglucose insulin secretion; increased lipolysis; higher glucose, glucagon, and proinsulin; higher TGs; lower HDL cholesterol (HDL-C); and higher γ GT, ALAT, and FLI (Fig. 2). Thus, an increase in this ratio was associated with a high loading of the HI.

Finally, in order to get a quantitative estimate of the impact of a high 12α-hydroxy/non–12α-hydroxy ratio, we compared the upper and lower quartiles of the ratio. Individuals in the upper quartile (a fourfold increased ratio, associated with significant increments in total BA levels and in the ratio of unconjugated/conjugated and primary/secondary) (Fig. 3) showed no difference in BMI compared with the lowest quartile, but had higher insulin, free fatty acids, TGs, and FLI and lower M value, HDL-C, and adiponectin (Fig. 4). Overall, these data show that increased BA 12α-hydroxylation is associated with the full complement of metabolic features of IR, independently of BMI.

**Diabetic patients.** T2D patients in our cohort were older and heavier than healthy controls and showed fasting hyperglycemia and hyperinsulinemia, and severe insulin resistance. These patients were on treatment with insulin utilization and ketogenesis but not closely with parameters of glucose metabolism or insulin sensitivity. The third factor in this analysis, characterized by high levels of acyl-glycerophosphocholines and transaminases, was associated with a high loading of the HI.

### TABLE 2
Serum BA concentrations in healthy subjects (all, n = 200, and by quartile of insulin sensitivity, Q1–Q4) and in patients with T2D (n = 35)

|                        | Healthy subjects | T2D patients |
|------------------------|------------------|--------------|
|                        | All              | Q1           | Q2           | Q3           | Q4           |
| Age (years)            | 46 ± 8           | 46 ± 9       | 45 ± 8       | 46 ± 9       | 53 ± 7***    |
| BMI (kg/m²)            | 25.0 ± 3.5       | 27.0 ± 3.5   | 25.3 ± 3.3   | 23.9 ± 3.2   | 23.7 ± 2.9   | 38.3 ± 12.3*** |
| FPG (mmol/L)           | 5.0 ± 0.5        | 5.1 ± 0.5    | 5.1 ± 0.5    | 5.0 ± 0.5    | 5.0 ± 0.4    | 9.7 ± 3.2***   |
| FPI (μmol/L)           | 29 (21)          | 43 (23)      | 32 (16)      | 26 (14)      | 22 (12)      | 94 (89)***     |
| M/I (units)            | 134 (88)         | 86 (26)      | 119 (14)     | 154 (24)     | 217 (51)     | 36 (19)**      |
| CDCA (μmol/L)          | 0.09 (0.21)      | 0.10 (0.25)  | 0.12 (0.24)  | 0.10 (0.21)  | 0.06 (0.14)  | 0.17 (0.91)**  |
| Glycocholic acid (GCDCA) (μmol/L) | 0.31 (0.32) | 0.31 (0.31) | 0.30 (0.33) | 0.32 (0.36) | 0.30 (0.28) | 0.57 (0.56)*** |
| Taurocholic acid (TCDDA) (μmol/L) | 0.03 (0.05) | 0.04 (0.04) | 0.04 (0.06) | 0.03 (0.04) | 0.03 (0.05) | 0.06 (0.06)*** |
| UDCA (μmol/L)          | 0.02 (0.04)      | 0.02 (0.05)  | 0.02 (0.05)  | 0.02 (0.03)  | 0.01 (0.03)  | 0.05 (0.09)*   |
| Hyodeoxycholic acid (HDCA) (μmol/L) | 0.04 (0.05) | 0.06 (0.07) | 0.03 (0.03) | 0.03 (0.04) | 0.03 (0.05) | 0.04 (0.05)    |
| LCA (μmol/L)           | 0.01 (0.02)      | 0.01 (0.02)  | 0.01 (0.02)  | 0.01 (0.02)  | 0.01 (0.02)  | 0.01 (0.01)    |
| Tauroliothocholic acid (TLCA) (μmol/L) | 0.01 (0.00) | 0.01 (0.00) | 0.01 (0.00) | 0.01 (0.00) | 0.01 (0.00) | 0.01 (0.00)    |
| CA (μmol/L)            | 0.05 (0.14)      | 0.08 (0.17)  | 0.06 (0.12)  | 0.04 (0.14)  | 0.04 (0.10)  | 0.04 (0.16)    |
| Glycocholic acid (GCA) (μmol/L) | 0.08 (0.10) | 0.09 (0.09) | 0.10 (0.14) | 0.08 (0.11) | 0.07 (0.07) | 0.15 (0.19)**  |
| Taurocholic acid (TCA) (μmol/L) | 0.01 (0.02) | 0.01 (0.02) | 0.01 (0.02) | 0.01 (0.02) | 0.01 (0.02) | 0.04 (0.03)**  |
| DCA (μmol/L)           | 0.20 (0.27)      | 0.26 (0.28)  | 0.20 (0.21)  | 0.19 (0.29)  | 0.15 (0.26)  | 0.33 (0.52)**  |
| Glycodeoxycholic acid (GCDCA) (μmol/L) | 0.10 (0.15) | 0.14 (0.16) | 0.12 (0.20) | 0.09 (0.14) | 0.09 (0.12) | 0.19 (0.30)*   |
| Tauroheoxycholic acid (TDCA) (μmol/L) | 0.02 (0.03) | 0.02 (0.02) | 0.02 (0.03) | 0.02 (0.03) | 0.01 (0.02) | 0.03 (0.05)*** |
| Σ BA (μmol/L)           | 1.14 (1.20)      | 1.32 (1.28)  | 1.06 (1.25)  | 1.15 (1.32)  | 0.99 (0.84)  | 2.02 (2.60)**  |
| Σ Primary BA (μmol/L)   | 0.66 (0.77)      | 0.70 (0.84)  | 0.65 (0.64)  | 0.70 (0.84)  | 0.57 (0.59)  | 1.39 (1.59)**  |
| Σ Unconjugated BA (μmol/L) | 0.50 (0.58) | 0.64 (0.72) | 0.48 (0.47) | 0.50 (0.61) | 0.34 (0.54) | 0.94 (1.28)*** |
| Σ 12α (μmol/L)          | 0.59 (0.68)      | 0.72 (0.66)  | 0.56 (0.75)  | 0.56 (0.73)  | 0.45 (0.51)  | 0.82 (1.16)**  |
| Primary/secondary       | 1.68 (2.24)      | 1.00 (2.53)  | 1.40 (1.80)  | 1.82 (2.42)  | 2.15 (2.24)  | 1.74 (1.96)    |
| Unconjugated/conjugated | 0.86 (0.95)      | 0.86 (1.10)  | 0.89 (0.76)  | 0.90 (0.84)  | 0.66 (1.27)  | 0.91 (1.04)    |
| 12α/non-12α             | 0.98 (0.74)      | 1.12 (0.91)  | 0.96 (0.65)  | 0.97 (0.86)  | 0.84 (0.61)  | 0.91 (0.67)    |
| HI                      | 0.47 (0.07)      | 0.47 (0.08)  | 0.46 (0.06)  | 0.47 (0.08)  | 0.46 (0.08)  | 0.50 (0.05)*** |

FPG, fasting plasma glucose; FPI, fasting insulin; M/I, clamp-derived insulin sensitivity. *0.02 < P < 0.05, **0.01 < P < 0.02, ***0.001 < P < 0.01, for the difference among quartiles of insulin sensitivity (Q1–Q4) (Kruskal-Wallis test). *0.02 < P < 0.05, **0.01 < P < 0.02, ***0.001 < P < 0.01, for the difference between T2D and healthy subjects (all) (Mann-Whitney test).
antidiabetic medications, a potential confounding factor.

In this group, there was a twofold increase in total plasma BAs (Table 2 and Fig. 5), as well as increases of 9 out of the 13 individual BAs measured. However, we found no disproportionate alterations in BA subtypes, such as 12α-hydroxylated versus non–12α-hydroxylated, unconjugated versus conjugated, or secondary versus primary BAs. To correct for potential confounders introduced by differences in BMI, we reanalyzed the data by comparing T2D patients to a subgroup of BMI-matched healthy subjects. However, we still found no disproportionate increase in 12α-hydroxylated BAs (data not shown). In contrast, the HI was significantly higher in the T2D groups than in the healthy control subjects regardless of covariate adjustment (Table 2).

Finally, we examined the relationship between insulin sensitivity and BA 12α-hydroxylation in the whole dataset, including healthy subjects and T2D patients. In multivariate analysis controlling for sex, age, BMI, and glucose tolerance status, we found that higher ratios of 12α-hydroxy/non–12α-hydroxy BAs, but not total BAs, primary versus secondary, or conjugated versus unconjugated...
BAs, were associated with lower insulin sensitivity (Fig. 6A) and higher plasma TG levels (Fig. 6B). As plasma TGs were twice as high in T2D patients as in controls (1.59 [0.81] vs. 0.85 [0.56] mmol/L, \( P < 0.0001 \)), we tested whether the HI might be related to the hypertriglyceridemia. In a multivariate regression model adjusting for sex, age, and BMI but also for fasting plasma glucose concentrations and the 12\( \alpha \)-hydroxyl/non–12\( \alpha \)-hydroxy BA, a higher HI was positively related to higher plasma TG levels (Fig. 6C).

![Comparison of BA characteristics between subjects in the top (red bars) and bottom quartile (blue bars) of the distribution of the 12\( \alpha \)-hydroxy/non–12\( \alpha \)-hydroxy ratio in 200 nondiabetic subjects. Bar plots are median and interquartile range for the variables listed on the left-hand side. ***0.01 \( P \geq 0.001 \), by Kruskal-Wallis test. GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid.](image1)

![Comparison of metabolic variables between subjects in the top (red bars) and bottom quartile (blue bars) of the distribution of the 12\( \alpha \)-hydroxy/non–12\( \alpha \)-hydroxy ratio in 200 nondiabetic subjects. Bar plots are median and interquartile range for the variables listed on the left-hand side. *0.05 \( P > 0.02 \); **0.02 \( P > 0.01 \), by Kruskal-Wallis test. FFA, free fatty acid; M/I, clamp-derived insulin sensitivity (in units of \( \mu \)mol \( \cdot \)min\(^{-1} \) \( \cdot \)kg\(^{-1} \) \( \cdot \)m\(^{-1} \)).](image2)
DISCUSSION

In this work, we show that in nondiabetic subjects, plasma 12α-hydroxylated BAs are disproportionately increased in association with IR. This finding provides evidence that BA composition is altered within the normal range of insulin sensitivity, and is consistent with insulin-dependent regulation of the 12α-hydroxylase CYP8B1. Our prior work has shown that Cyp8b1 is a target gene of transcription factor FoxO1, whose ability to promote Cyp8b1 transcription is inhibited by insulin via Akt-dependent phosphorylation and nuclear exclusion of FoxO1 (12). These findings dovetail with earlier studies of BA composition, as increased 12α-hydroxylated BAs have been observed in mice lacking hepatic insulin receptors and rodent models of diabetes (13–17). Because FoxO is expected to be more active in IR, owing to decreased Akt-mediated nuclear exclusion, the finding that FoxO1 activates Cyp8b1 reveals a plausible mechanism for upregulation of 12α-hydroxylated BA synthesis in these models.

Surprisingly, a preferential increase in 12α-hydroxylated BAs did not emerge from sampling T2D patients, as we did not find disproportionate increases in these molecules relative to non–12α-hydroxylated BAs despite the marked IR (Table 2). These findings suggest that plasma BA levels and composition are affected by other aspects of T2D in addition to IR. We also note limitations of our study that may confound these results. First, the 35 diabetic patients in our study were taking antidiabetic medications, which may affect BA synthesis and turnover through liver insulin sensitization or other indirect effects. Second, our measurements used fasting rather than postprandial plasma, which may mask some of the differences. A previous study of 16 T2D patients showed increased synthesis of CA and input rate of DCA as compared with BMI-matched controls, causing an increase in postprandial plasma DCA levels and an apparent increase in the 12α-hydroxy/non–12α-hydroxy ratio, but no difference in total plasma BAs (28). In a recent metabolomics screen of 40 subjects with self-reported diabetes (29), DCA, but not CA, was detectable in a higher number of diabetic subjects as compared with a group of 60 control nondiabetic subjects (consistent with the higher levels we observed) (Table 2), but total BAs were not measured; thus a relative preponderance of 12α-hydroxylated species was not reported (29). In addition to medications and postprandial versus fasting plasma, other differences in our study population may account for differences in our findings, such as time since diabetes diagnosis, metabolic control, recruiting period, and geographic location. Moreover, an increased synthesis of 12α-hydroxylated BAs may not be reflected in steady-state plasma levels, because plasma levels are determined by multiple factors, including rate of reabsorption.
in the small intestine and rate of reuptake in the liver sinusoids. Tracer studies will be required to address these possibilities. On the other hand, evidence from genetically obese T2D ob/ob mice is consistent with the increase in total plasma BAs that we observed; in these mice, the hyperglycemia epigenetically augments expression of Cyp7a1, the rate-limiting enzyme of BA synthesis, whereby BA synthesis and serum BA concentrations are increased (17). FoxO1 has also been implicated in promoting expression of Cyp7a1, although the direction of this effect is debated and may be different between mice and humans (30,31).

Mechanistically, it bears emphasizing that FoxO1 is regulated by both insulin and glucose, and that the lack of a preferential increase in 12α-hydroxylated BAs seen in our study could be explained by hyperglycemia-induced FoxO degradation, and thus inability to fully activate CYP8B1 (32,33).

Of interest is the finding that the HI was significantly higher in T2D patients as compared with nondiabetic subjects, due to the higher circulating levels of DCA and its conjugated forms, relative to CA, CDCA, and their conjugates (Table 2). More hydrophobic BA species are more toxic, especially to the liver (34,35). Hydrophobic BAs are also better able to cross, and are more disruptive to, cell membranes (35,36); are more likely to activate additional BA-sensitive signaling pathways such as protein kinase C, extracellular signal–related kinase 1/2, PXR, and VDR (7,34,37); and are more efficient in absorption of dietary lipids (18). The observed association of the HI with raised transaminases and circulating phospholipid concentrations (Fig. 2) plausibly tracks with this notion. The independent relationship of the HI to TGs is also of interest, although we are unaware of mechanistic data linking BA hydrophobicity to fasting TG levels.

In healthy subjects, we show that an increased ratio of 12α-hydroxy/non–12α-hydroxy BAs is associated with classic features of IR. These include metabolic functions known to be influenced by BAs, including insulin secretion, TG levels, and HDL-C turnover (1,38,39). In comparison, changes in total BA levels were more closely related to changes in fatty acid utilization and ketogenesis. The implications of these findings are that changes in BA types may be an important feature in the pathophysiology of IR, and that the effects of these changes may be dissociable from the effects of altering total BA levels. In addition, the identification of altered 12α-hydroxy BA levels in euglycemic/insulin-resistant individuals may be exploited as a biomarker of hepatic insulin sensitivity and CVD risk.

Mechanistic studies will be required to identify whether and how BA composition affects metabolic abnormalities that arise in IR. However, we speculate that changes in endogenous ligands for BA receptors affect a wide range of BA-regulated pathways. It has been shown that in HepG2 cells, a variety of different BA species can effectively repress Cyp7a1, the rate-limiting step of BA synthesis (40); thus, this pathway is likely to be sensitive to total BA levels. On the other hand, BA species differ considerably in their ability to activate transcription of Bsep, the bile salt export pump, and CDCA is the best activator, through its potent activation of FXR (40). Interestingly, DCA, the most abundant plasma 12α-hydroxylated BA, which we found to be increased in IR, has been shown to interfere with the ability of CDCA to cause recruitment of coactivator SRC-1 to FXR (20). Is it possible that the increases in DCA during IR cause a decline in activation of some FXR pathways? Interventional studies will be required to address this important question.

In addition to alterations in FXR ligands during IR, there may be effects directly on FXR mRNA (Nr1h4), which has been shown to be regulated by glucose and insulin. In three rodent models of hyperglycemia, streptozotocin-induced diabetic rats, diabetic Zucker rats, and liver insulin receptor knockout mice, liver FXR expression is reduced (14,41). Insulin treatment normalizes this defect in streptozotocin-treated rats (41). It is possible that a hyperglycemia-induced reduction in liver FXR mRNA may contribute to metabolic outcomes during diabetes, such as a release of FXR-mediated repression of Cyp7a1 and subsequent increase in BA synthesis (41). Finally, evidence now suggests a role for β-cell FXR in insulin secretion; perhaps changes in FXR ligands or mRNA expression during IR impair glucose-stimulated insulin secretion (38,39,42).

Overall, these findings support a model whereby insulin regulates the production of endogenous 12α-hydroxy BAs that subsequently affect metabolism in multiple ways. The relationship between these metabolites and other phenotypes of IR warrants further investigation. It is conceivable that BA composition could be a target for new therapeutic intervention in IR.

ACKNOWLEDGMENTS

This work was supported in part by Columbia Clinical and Translational Science Award Grant UL1-TR-000040 (National Center for Advancing Translational Sciences/National Institutes of Health [NIH]), DK-63608 (NIH), the Schaefer Scholar Award, a Core Usage Funding Award from Columbia University College of Physicians and Surgeons, and K09-HL-111206 (NIH).

E.F. has served as a speaker and consultant for Boehringer Ingelheim, Merck, Sanofi, Eli Lilly and Company, Johnson & Johnson, Astellas, Daiichi Sankyo, Bristol-Myers-Squibb/AstraZeneca, and Novartis. No other potential conflicts of interest relevant to this article were reported.

R.A.H. conceived of this study, designed and implemented experiments, analyzed data, and wrote the manuscript. B.A. and S.C. performed the in vivo studies, contributed to discussions, and edited the manuscript. D.A. contributed to discussions and edited the manuscript. E.F. is the principal investigator of the RISC study, designed experiments, analyzed data, and wrote the manuscript. R.A.H. and E.F. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

This work was presented at the 73rd Scientific Sessions of the American Diabetes Association, Chicago, Illinois, 21–25 June 2013.

The authors wish to express their gratitude to the investigators of the RISC study, who originally carried out the phenotyping of the nondiabetic subjects.

REFERENCES

1. Ledebore P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147–191.
2. Gregor MF, Hotamisligil GS. Thematic review series: adipocyte biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007;48:1905–1914.
3. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012;53:1725–1737.
10. Hofmann AF, Roda A. Physicochemical properties of bile acids and their

13. Akiyoshi T, Uchida K, Takase H, Nomura Y, Takeuchi N. Cholesterol

12. Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired

15. Uchida K, Makino S, Akiyoshi T. Altered bile acid metabolism in nonobese,

22. Rebelos E, Muscelli E, Natali A, et al.; RISC Study Investigators. Body

20. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for

18. Wang DQ, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic

23. Ferrannini E, Mari A, Camastra S, et al. Early metabolic markers of the
devlopment of dysglycemia and type 2 diabetes and their physiological

14. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly

35. Billington D, Evans CE, Godfrey PP, Coleman R. Effects of bile salts on

28. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with
colesevelam treatment in patients with type 2 diabetes is not directly as-

26. Ferrannini E, Natali A, Camastra S, et al.; RISC Investigators. In

24. Mari A, Tura A, Natali A, et al.; RISC Investigators. Influence of hyper-

25. Gaspardelli A, Koizaka M, Hjellvik K, et al.; RISC Investigators. Fatty liver

16. Out C, Groen AK, Brufau G. Bile acid sequestrants: more than simple

19. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal in-
terposition surgery increases bile acid recycling and protects against

17. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal in-
terposition surgery increases bile acid recycling and protects against

8. Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in

6. Out C, Groen AK, Bianco AC, et al. Serum bile acids are higher in

7. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting

4. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver dis-

5. Hofmann AF. The continuing importance of bile acids in liver and in-
testinal disease. Arch Intern Med 1999;159:2647–2658

6. Out C, Groen AK, Bianco AC, et al. Serum bile acids are higher in

37. Akare S, Martinez JD. Bile acid induces hydrophobicity-dependent mem-

36. Vyvoda OS, Coleman R, Holdsworth G. Effects of different bile salts upon

35. Billington D, Evans CE, Godfrey PP, Coleman R. Effects of bile salts on

34. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as

33. Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancre-
atic beta cell failure through NeuroD and MafA induction. Cell Metab 2005;

32. Akare S, Martinez JD. Bile acid induces hydrophobicity-dependent mem-

31. Shinn DJ, Osborne TF. FGFI5/FGF8 integrates growth factor signaling

30. Wang DQ, Tanuma S, Cohen DE, Carey MC. Feeding natural hydrophilic

29. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes:

28. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with
colesevelam treatment in patients with type 2 diabetes is not directly as-

27. Heuman DM. Quantitative expression of the hydrophilic-hydrophobic bal-

26. Ferrannini E, Natali A, Camastra S, et al.; RISC Investigators. Early metabolic markers of the
devlopment of dysglycemia and type 2 diabetes and their physiological

25. Gaspardelli A, Koizaka M, Hjellvik K, et al.; RISC Investigators. Fatty liver

24. Mari A, Tura A, Natali A, et al.; RISC Investigators. Influence of hyper-

23. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the
devlopment of dysglycemia and type 2 diabetes and their physiological

22. Rebelos E, Muscelli E, Natali A, et al.; RISC Study Investigators. Body

21. Li T, Franci JM, Boehme S, et al. Glucose and insulin induction of bile acid

20. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for

19. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal in-
terposition surgery increases bile acid recycling and protects against

18. Wang DQ, Tanuma S, Cohen DE, Carey MC. Feeding natural hydrophilic

17. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal in-
terposition surgery increases bile acid recycling and protects against

16. Out C, Groen AK, Bianco AC, et al. Serum bile acids are higher in

15. Uchida K, Makino S, Akiyoshi T. Altered bile acid metabolism in nonobese,

14. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly

13. Akiyoshi T, Uchida K, Takase H, Nomura Y, Takeuchi N. Cholesterol
gallstones in alloxan-diabetic mice. J Lipid Res 1986;27:915

12. Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired
generation of 12-hydroxylated bile acids links hepatic insulin signaling

11. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid

10. Hofmann AF, Roda A. Physicochemical properties of bile acids and their

9. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal in-
terposition surgery increases bile acid recycling and protects against

8. Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in

7. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting

6. Out C, Groen AK, Bianco AC, et al. Serum bile acids are higher in

5. Hofmann AF. The continuing importance of bile acids in liver and in-
testinal disease. Arch Intern Med 1999;159:2647–2658

4. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver dis-

3. Haseusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired
generation of 12-hydroxylated bile acids links hepatic insulin signaling

2. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver dis-

1. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver dis-

4191, DIABETES, VOL. 62, DECEMBER 2013